Stockscreener 앱 받기
0.00
100.00%
-0.39
시간 외 거래:
.39
0.39
+
전일 마감가:
$0.39
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
-
순이익/손실:
$-37.07M
주가수익비율:
0.00
EPS:
-13.73
순현금흐름:
$-23.91M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-97.12%
1년 성능:
-95.25%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$0.498
실로스 테라 Stock (SEEL) Company Profile
SEEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEEL
Seelos Therapeutics Inc
|
0.00 | 0 | 0 | -37.07M | -23.91M | -13.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
실로스 테라 Stock (SEEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-27 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-07-01 | 개시 | Guggenheim | Buy |
| 2021-06-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-03-30 | 개시 | B. Riley Securities | Buy |
| 2019-11-14 | 개시 | The Benchmark Company | Speculative Buy |
| 2019-05-14 | 개시 | ROTH Capital | Buy |
모두보기
실로스 테라 주식(SEEL)의 최신 뉴스
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week LowHere's Why - MSN
J&J Expands Ketamine Case With Spravato Monotherapy Indication - insights.citeline.com
SEELQ (Seelos Therapeutics) PS Ratio : (As of Jan. 06, 2025) - GuruFocus.com
Seelos Therapeutics (NASDAQ:SEEL) Stock Price Down 4.3% – Time to Sell? - Defense World
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - The Eastern Progress Online
PTC halts development of ALS drug after trial miss - The Pharma Letter
SEELQ (Seelos Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Seelos Therapeutics files for Chapter 11 bankruptcy By Investing.com - Investing.com Canada
Seelos Therapeutics files for Chapter 11 bankruptcy - Investing.com
SEELQ (Seelos Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Operating Cash Flow per Share : $-234.50 (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Long-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Cash Flow from Financing : $7.73 Mil (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Shares Outstanding (EOP) : 0.21 Mil (As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Enterprise Value : $10.07 Mil (As of Nov. 21, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Free Cash Flow : $-13.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) EPS (Diluted) : $-475.52 (TTM As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) EV-to-Revenue : (As of Nov. 20, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) 14-Day RSI : 23.94 (As of Nov. 20, 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
SEELQ (Seelos Therapeutics) Preferred Stock : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
Seelos Announces Second Postponement of its Annual Meeting of St - GuruFocus.com
SEELQ (Seelos Therapeutics) 9-Day RSI : 19.65 (As of Nov. 21, 2024) - GuruFocus.com
Biopharm Co. Seelos Files For Ch. 11 After Nasdaq Delisting - Law360
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - Quantisnow
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split - GuruFocus.com
Seelos Announces Postponement of its Annual Meeting of Stockholders - GuruFocus.com
SEELOS THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Seelos Therapeutics announces the signing of a Material Transfer - GuruFocus.com
Seelos Announces Second Postponement of its Annual Meeting of Stockholders - StockTitan
Seelos Therapeutics (NASDAQ:SEEL) and Zoetis (NYSE:ZTS) Head-To-Head Contrast - Defense World
SEEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Closing Bell Recap: Seelos Therapeutics Inc (SEEL) Ends at 1.28, Reflecting a -47.76 Downturn - The Dwinnex
Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market - Benzinga
Seelos gets Nasdaq delisting notice - MSN
SEEL stock touches 52-week low at $2.37 amid market challenges By Investing.com - Investing.com South Africa
SEEL stock touches 52-week low at $2.37 amid market challenges - Investing.com
Seelos Therapeutics Inc (SEEL) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Financial Health Check: Examining Seelos Therapeutics Inc (SEEL)’s Key Ratios - The Dwinnex
Seelos Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Seelos Therapeutics faces Nasdaq delisting over share price - Investing.com
SEEL stock touches 52-week low at $2.77 amid market challenges By Investing.com - Investing.com South Africa
SEEL stock touches 52-week low at $2.77 amid market challenges - Investing.com Australia
Was Seelos Therapeutics Inc (SEEL)’s session last reading good? - US Post News
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected - Benzinga
Seelos Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa
Seelos Therapeutics approves reverse stock split - Investing.com India
Seelos Therapeutics Announces Reverse Stock Split and Adjustments - TipRanks
실로스 테라 (SEEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):